Bold Therapeutics Ruthenium Cancer Compound Patent EP3423055A1
Summary
The European Patent Office published patent EP3423055A1 granted to Bold Therapeutics Inc. covering trans-[tetrachlorobis(1H-indazole)ruthenate (III)] for cancer treatment. The patent protects the use of this ruthenium-based compound across 36 designated European states including Germany, France, UK, Italy, Spain, Netherlands, and Sweden.
What changed
The European Patent Office published patent application EP3423055A1 for Bold Therapeutics Inc., covering the use of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] in cancer treatment. The patent includes claims across multiple IPC classifications spanning ruthenium-based chemotherapy agents (A61K 33/14), protein therapeutics (A61K 38/20, A61K 38/21), antibody therapies (C07K 16/28, A61K 39/395), and cancer-specific applications (A61P 35/00). Inventors are Suzanne Bakewell and Jyothi Sethuraman.
Pharmaceutical companies developing metal-based oncology therapeutics should consider this patent when designing compounds in the ruthenium indazole space. The broad IPC coverage indicates protection extending from the base compound through combination therapies and antibody conjugates, potentially limiting competitive development paths in this therapeutic area across European markets.
What to do next
- Monitor patent portfolio for competitive ruthenium cancer compounds
- Review freedom-to-operate for oncology drug development
- Assess licensing opportunities for EP3423055A1
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)]FOR THE TREATMENT OF CANCER
Publication EP3423055A1 Kind: A1 Apr 01, 2026
Applicants
Bold Therapeutics Inc.
Inventors
BAKEWELL, Suzanne, SETHURAMAN, Jyothi
IPC Classifications
A61K 31/416 20060101AFI20190910BHEP A61K 51/04 20060101ALI20190910BHEP A61K 33/14 20060101ALI20190910BHEP A61K 39/395 20060101ALI20190910BHEP A61K 38/20 20060101ALI20190910BHEP A61K 38/21 20060101ALI20190910BHEP C07K 16/28 20060101ALI20190910BHEP A61P 35/00 20060101ALI20190910BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.